Global Inactivated Vaccine Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Inactivated Vaccine market size was valued at US$ 5688.3 million in 2023. With growing demand in downstream market, the Inactivated Vaccine is forecast to a readjusted size of US$ 7199.6 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Inactivated Vaccine market. Inactivated Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Inactivated Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Inactivated Vaccine market.
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Inactivated Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Inactivated Vaccine market. It may include historical data, market segmentation by Type (e.g., Children Inactivated Vaccine, Adult Inactivated Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Inactivated Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Inactivated Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Inactivated Vaccine industry. This include advancements in Inactivated Vaccine technology, Inactivated Vaccine new entrants, Inactivated Vaccine new investment, and other innovations that are shaping the future of Inactivated Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Inactivated Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Inactivated Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Inactivated Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Inactivated Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Inactivated Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Inactivated Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Inactivated Vaccine market.
Market Segmentation:
Inactivated Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Inactivated Vaccine market size was valued at US$ 5688.3 million in 2023. With growing demand in downstream market, the Inactivated Vaccine is forecast to a readjusted size of US$ 7199.6 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Inactivated Vaccine market. Inactivated Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Inactivated Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Inactivated Vaccine market.
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Inactivated Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Inactivated Vaccine market. It may include historical data, market segmentation by Type (e.g., Children Inactivated Vaccine, Adult Inactivated Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Inactivated Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Inactivated Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Inactivated Vaccine industry. This include advancements in Inactivated Vaccine technology, Inactivated Vaccine new entrants, Inactivated Vaccine new investment, and other innovations that are shaping the future of Inactivated Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Inactivated Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Inactivated Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Inactivated Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Inactivated Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Inactivated Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Inactivated Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Inactivated Vaccine market.
Market Segmentation:
Inactivated Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Children Inactivated Vaccine
- Adult Inactivated Vaccine
- Hospital
- Medical Center
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Pharma(Japan)
- CSL Limited(Australia)
- Emergent BioSolutions(U.S.)
- GlaxoSmithKline(U.K.)
- Johnson & Johnson(U.S.)
- MedImmune(U.S.)
- Merck & Co(U.S.)
- Pfizer(U.S.)
- Sanofi Pasteur(France)
- Serum Institute of India Pvt(India)
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Inactivated Vaccine Market Size 2019-2030
2.1.2 Inactivated Vaccine Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Inactivated Vaccine Segment by Type
2.2.1 Children Inactivated Vaccine
2.2.2 Adult Inactivated Vaccine
2.3 Inactivated Vaccine Market Size by Type
2.3.1 Inactivated Vaccine Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Inactivated Vaccine Market Size Market Share by Type (2019-2024)
2.4 Inactivated Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Medical Center
2.5 Inactivated Vaccine Market Size by Application
2.5.1 Inactivated Vaccine Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Inactivated Vaccine Market Size Market Share by Application (2019-2024)
3 INACTIVATED VACCINE MARKET SIZE BY PLAYER
3.1 Inactivated Vaccine Market Size Market Share by Players
3.1.1 Global Inactivated Vaccine Revenue by Players (2019-2024)
3.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global Inactivated Vaccine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 INACTIVATED VACCINE BY REGIONS
4.1 Inactivated Vaccine Market Size by Regions (2019-2024)
4.2 Americas Inactivated Vaccine Market Size Growth (2019-2024)
4.3 APAC Inactivated Vaccine Market Size Growth (2019-2024)
4.4 Europe Inactivated Vaccine Market Size Growth (2019-2024)
4.5 Middle East & Africa Inactivated Vaccine Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Inactivated Vaccine Market Size by Country (2019-2024)
5.2 Americas Inactivated Vaccine Market Size by Type (2019-2024)
5.3 Americas Inactivated Vaccine Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inactivated Vaccine Market Size by Region (2019-2024)
6.2 APAC Inactivated Vaccine Market Size by Type (2019-2024)
6.3 APAC Inactivated Vaccine Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Inactivated Vaccine by Country (2019-2024)
7.2 Europe Inactivated Vaccine Market Size by Type (2019-2024)
7.3 Europe Inactivated Vaccine Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Inactivated Vaccine by Region (2019-2024)
8.2 Middle East & Africa Inactivated Vaccine Market Size by Type (2019-2024)
8.3 Middle East & Africa Inactivated Vaccine Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL INACTIVATED VACCINE MARKET FORECAST
10.1 Global Inactivated Vaccine Forecast by Regions (2025-2030)
10.1.1 Global Inactivated Vaccine Forecast by Regions (2025-2030)
10.1.2 Americas Inactivated Vaccine Forecast
10.1.3 APAC Inactivated Vaccine Forecast
10.1.4 Europe Inactivated Vaccine Forecast
10.1.5 Middle East & Africa Inactivated Vaccine Forecast
10.2 Americas Inactivated Vaccine Forecast by Country (2025-2030)
10.2.1 United States Inactivated Vaccine Market Forecast
10.2.2 Canada Inactivated Vaccine Market Forecast
10.2.3 Mexico Inactivated Vaccine Market Forecast
10.2.4 Brazil Inactivated Vaccine Market Forecast
10.3 APAC Inactivated Vaccine Forecast by Region (2025-2030)
10.3.1 China Inactivated Vaccine Market Forecast
10.3.2 Japan Inactivated Vaccine Market Forecast
10.3.3 Korea Inactivated Vaccine Market Forecast
10.3.4 Southeast Asia Inactivated Vaccine Market Forecast
10.3.5 India Inactivated Vaccine Market Forecast
10.3.6 Australia Inactivated Vaccine Market Forecast
10.4 Europe Inactivated Vaccine Forecast by Country (2025-2030)
10.4.1 Germany Inactivated Vaccine Market Forecast
10.4.2 France Inactivated Vaccine Market Forecast
10.4.3 UK Inactivated Vaccine Market Forecast
10.4.4 Italy Inactivated Vaccine Market Forecast
10.4.5 Russia Inactivated Vaccine Market Forecast
10.5 Middle East & Africa Inactivated Vaccine Forecast by Region (2025-2030)
10.5.1 Egypt Inactivated Vaccine Market Forecast
10.5.2 South Africa Inactivated Vaccine Market Forecast
10.5.3 Israel Inactivated Vaccine Market Forecast
10.5.4 Turkey Inactivated Vaccine Market Forecast
10.5.5 GCC Countries Inactivated Vaccine Market Forecast
10.6 Global Inactivated Vaccine Forecast by Type (2025-2030)
10.7 Global Inactivated Vaccine Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Astellas Pharma(Japan)
11.1.1 Astellas Pharma(Japan) Company Information
11.1.2 Astellas Pharma(Japan) Inactivated Vaccine Product Offered
11.1.3 Astellas Pharma(Japan) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Astellas Pharma(Japan) Main Business Overview
11.1.5 Astellas Pharma(Japan) Latest Developments
11.2 CSL Limited(Australia)
11.2.1 CSL Limited(Australia) Company Information
11.2.2 CSL Limited(Australia) Inactivated Vaccine Product Offered
11.2.3 CSL Limited(Australia) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 CSL Limited(Australia) Main Business Overview
11.2.5 CSL Limited(Australia) Latest Developments
11.3 Emergent BioSolutions(U.S.)
11.3.1 Emergent BioSolutions(U.S.) Company Information
11.3.2 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Offered
11.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Emergent BioSolutions(U.S.) Main Business Overview
11.3.5 Emergent BioSolutions(U.S.) Latest Developments
11.4 GlaxoSmithKline(U.K.)
11.4.1 GlaxoSmithKline(U.K.) Company Information
11.4.2 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Offered
11.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GlaxoSmithKline(U.K.) Main Business Overview
11.4.5 GlaxoSmithKline(U.K.) Latest Developments
11.5 Johnson & Johnson(U.S.)
11.5.1 Johnson & Johnson(U.S.) Company Information
11.5.2 Johnson & Johnson(U.S.) Inactivated Vaccine Product Offered
11.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Johnson & Johnson(U.S.) Main Business Overview
11.5.5 Johnson & Johnson(U.S.) Latest Developments
11.6 MedImmune(U.S.)
11.6.1 MedImmune(U.S.) Company Information
11.6.2 MedImmune(U.S.) Inactivated Vaccine Product Offered
11.6.3 MedImmune(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 MedImmune(U.S.) Main Business Overview
11.6.5 MedImmune(U.S.) Latest Developments
11.7 Merck & Co(U.S.)
11.7.1 Merck & Co(U.S.) Company Information
11.7.2 Merck & Co(U.S.) Inactivated Vaccine Product Offered
11.7.3 Merck & Co(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Merck & Co(U.S.) Main Business Overview
11.7.5 Merck & Co(U.S.) Latest Developments
11.8 Pfizer(U.S.)
11.8.1 Pfizer(U.S.) Company Information
11.8.2 Pfizer(U.S.) Inactivated Vaccine Product Offered
11.8.3 Pfizer(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Pfizer(U.S.) Main Business Overview
11.8.5 Pfizer(U.S.) Latest Developments
11.9 Sanofi Pasteur(France)
11.9.1 Sanofi Pasteur(France) Company Information
11.9.2 Sanofi Pasteur(France) Inactivated Vaccine Product Offered
11.9.3 Sanofi Pasteur(France) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sanofi Pasteur(France) Main Business Overview
11.9.5 Sanofi Pasteur(France) Latest Developments
11.10 Serum Institute of India Pvt(India)
11.10.1 Serum Institute of India Pvt(India) Company Information
11.10.2 Serum Institute of India Pvt(India) Inactivated Vaccine Product Offered
11.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Serum Institute of India Pvt(India) Main Business Overview
11.10.5 Serum Institute of India Pvt(India) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Inactivated Vaccine Market Size 2019-2030
2.1.2 Inactivated Vaccine Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Inactivated Vaccine Segment by Type
2.2.1 Children Inactivated Vaccine
2.2.2 Adult Inactivated Vaccine
2.3 Inactivated Vaccine Market Size by Type
2.3.1 Inactivated Vaccine Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Inactivated Vaccine Market Size Market Share by Type (2019-2024)
2.4 Inactivated Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Medical Center
2.5 Inactivated Vaccine Market Size by Application
2.5.1 Inactivated Vaccine Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Inactivated Vaccine Market Size Market Share by Application (2019-2024)
3 INACTIVATED VACCINE MARKET SIZE BY PLAYER
3.1 Inactivated Vaccine Market Size Market Share by Players
3.1.1 Global Inactivated Vaccine Revenue by Players (2019-2024)
3.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global Inactivated Vaccine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 INACTIVATED VACCINE BY REGIONS
4.1 Inactivated Vaccine Market Size by Regions (2019-2024)
4.2 Americas Inactivated Vaccine Market Size Growth (2019-2024)
4.3 APAC Inactivated Vaccine Market Size Growth (2019-2024)
4.4 Europe Inactivated Vaccine Market Size Growth (2019-2024)
4.5 Middle East & Africa Inactivated Vaccine Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Inactivated Vaccine Market Size by Country (2019-2024)
5.2 Americas Inactivated Vaccine Market Size by Type (2019-2024)
5.3 Americas Inactivated Vaccine Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inactivated Vaccine Market Size by Region (2019-2024)
6.2 APAC Inactivated Vaccine Market Size by Type (2019-2024)
6.3 APAC Inactivated Vaccine Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Inactivated Vaccine by Country (2019-2024)
7.2 Europe Inactivated Vaccine Market Size by Type (2019-2024)
7.3 Europe Inactivated Vaccine Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Inactivated Vaccine by Region (2019-2024)
8.2 Middle East & Africa Inactivated Vaccine Market Size by Type (2019-2024)
8.3 Middle East & Africa Inactivated Vaccine Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL INACTIVATED VACCINE MARKET FORECAST
10.1 Global Inactivated Vaccine Forecast by Regions (2025-2030)
10.1.1 Global Inactivated Vaccine Forecast by Regions (2025-2030)
10.1.2 Americas Inactivated Vaccine Forecast
10.1.3 APAC Inactivated Vaccine Forecast
10.1.4 Europe Inactivated Vaccine Forecast
10.1.5 Middle East & Africa Inactivated Vaccine Forecast
10.2 Americas Inactivated Vaccine Forecast by Country (2025-2030)
10.2.1 United States Inactivated Vaccine Market Forecast
10.2.2 Canada Inactivated Vaccine Market Forecast
10.2.3 Mexico Inactivated Vaccine Market Forecast
10.2.4 Brazil Inactivated Vaccine Market Forecast
10.3 APAC Inactivated Vaccine Forecast by Region (2025-2030)
10.3.1 China Inactivated Vaccine Market Forecast
10.3.2 Japan Inactivated Vaccine Market Forecast
10.3.3 Korea Inactivated Vaccine Market Forecast
10.3.4 Southeast Asia Inactivated Vaccine Market Forecast
10.3.5 India Inactivated Vaccine Market Forecast
10.3.6 Australia Inactivated Vaccine Market Forecast
10.4 Europe Inactivated Vaccine Forecast by Country (2025-2030)
10.4.1 Germany Inactivated Vaccine Market Forecast
10.4.2 France Inactivated Vaccine Market Forecast
10.4.3 UK Inactivated Vaccine Market Forecast
10.4.4 Italy Inactivated Vaccine Market Forecast
10.4.5 Russia Inactivated Vaccine Market Forecast
10.5 Middle East & Africa Inactivated Vaccine Forecast by Region (2025-2030)
10.5.1 Egypt Inactivated Vaccine Market Forecast
10.5.2 South Africa Inactivated Vaccine Market Forecast
10.5.3 Israel Inactivated Vaccine Market Forecast
10.5.4 Turkey Inactivated Vaccine Market Forecast
10.5.5 GCC Countries Inactivated Vaccine Market Forecast
10.6 Global Inactivated Vaccine Forecast by Type (2025-2030)
10.7 Global Inactivated Vaccine Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Astellas Pharma(Japan)
11.1.1 Astellas Pharma(Japan) Company Information
11.1.2 Astellas Pharma(Japan) Inactivated Vaccine Product Offered
11.1.3 Astellas Pharma(Japan) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Astellas Pharma(Japan) Main Business Overview
11.1.5 Astellas Pharma(Japan) Latest Developments
11.2 CSL Limited(Australia)
11.2.1 CSL Limited(Australia) Company Information
11.2.2 CSL Limited(Australia) Inactivated Vaccine Product Offered
11.2.3 CSL Limited(Australia) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 CSL Limited(Australia) Main Business Overview
11.2.5 CSL Limited(Australia) Latest Developments
11.3 Emergent BioSolutions(U.S.)
11.3.1 Emergent BioSolutions(U.S.) Company Information
11.3.2 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Offered
11.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Emergent BioSolutions(U.S.) Main Business Overview
11.3.5 Emergent BioSolutions(U.S.) Latest Developments
11.4 GlaxoSmithKline(U.K.)
11.4.1 GlaxoSmithKline(U.K.) Company Information
11.4.2 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Offered
11.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GlaxoSmithKline(U.K.) Main Business Overview
11.4.5 GlaxoSmithKline(U.K.) Latest Developments
11.5 Johnson & Johnson(U.S.)
11.5.1 Johnson & Johnson(U.S.) Company Information
11.5.2 Johnson & Johnson(U.S.) Inactivated Vaccine Product Offered
11.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Johnson & Johnson(U.S.) Main Business Overview
11.5.5 Johnson & Johnson(U.S.) Latest Developments
11.6 MedImmune(U.S.)
11.6.1 MedImmune(U.S.) Company Information
11.6.2 MedImmune(U.S.) Inactivated Vaccine Product Offered
11.6.3 MedImmune(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 MedImmune(U.S.) Main Business Overview
11.6.5 MedImmune(U.S.) Latest Developments
11.7 Merck & Co(U.S.)
11.7.1 Merck & Co(U.S.) Company Information
11.7.2 Merck & Co(U.S.) Inactivated Vaccine Product Offered
11.7.3 Merck & Co(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Merck & Co(U.S.) Main Business Overview
11.7.5 Merck & Co(U.S.) Latest Developments
11.8 Pfizer(U.S.)
11.8.1 Pfizer(U.S.) Company Information
11.8.2 Pfizer(U.S.) Inactivated Vaccine Product Offered
11.8.3 Pfizer(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Pfizer(U.S.) Main Business Overview
11.8.5 Pfizer(U.S.) Latest Developments
11.9 Sanofi Pasteur(France)
11.9.1 Sanofi Pasteur(France) Company Information
11.9.2 Sanofi Pasteur(France) Inactivated Vaccine Product Offered
11.9.3 Sanofi Pasteur(France) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sanofi Pasteur(France) Main Business Overview
11.9.5 Sanofi Pasteur(France) Latest Developments
11.10 Serum Institute of India Pvt(India)
11.10.1 Serum Institute of India Pvt(India) Company Information
11.10.2 Serum Institute of India Pvt(India) Inactivated Vaccine Product Offered
11.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Serum Institute of India Pvt(India) Main Business Overview
11.10.5 Serum Institute of India Pvt(India) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
.
Table 1. Inactivated Vaccine Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Children Inactivated Vaccine
Table 3. Major Players of Adult Inactivated Vaccine
Table 4. Inactivated Vaccine Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 7. Inactivated Vaccine Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 10. Global Inactivated Vaccine Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Inactivated Vaccine Revenue Market Share by Player (2019-2024)
Table 12. Inactivated Vaccine Key Players Head office and Products Offered
Table 13. Inactivated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Inactivated Vaccine Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Inactivated Vaccine Market Size Market Share by Regions (2019-2024)
Table 18. Global Inactivated Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Inactivated Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Inactivated Vaccine Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Inactivated Vaccine Market Size Market Share by Country (2019-2024)
Table 22. Americas Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 24. Americas Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 26. APAC Inactivated Vaccine Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Inactivated Vaccine Market Size Market Share by Region (2019-2024)
Table 28. APAC Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 30. APAC Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 32. Europe Inactivated Vaccine Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Inactivated Vaccine Market Size Market Share by Country (2019-2024)
Table 34. Europe Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 36. Europe Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Inactivated Vaccine Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Inactivated Vaccine Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Inactivated Vaccine
Table 45. Key Market Challenges & Risks of Inactivated Vaccine
Table 46. Key Industry Trends of Inactivated Vaccine
Table 47. Global Inactivated Vaccine Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Inactivated Vaccine Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Inactivated Vaccine Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Inactivated Vaccine Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Astellas Pharma(Japan) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 52. Astellas Pharma(Japan) Inactivated Vaccine Product Offered
Table 53. Astellas Pharma(Japan) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Astellas Pharma(Japan) Main Business
Table 55. Astellas Pharma(Japan) Latest Developments
Table 56. CSL Limited(Australia) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 57. CSL Limited(Australia) Inactivated Vaccine Product Offered
Table 58. CSL Limited(Australia) Main Business
Table 59. CSL Limited(Australia) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. CSL Limited(Australia) Latest Developments
Table 61. Emergent BioSolutions(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 62. Emergent BioSolutions(U.S.) Inactivated Vaccine Product Offered
Table 63. Emergent BioSolutions(U.S.) Main Business
Table 64. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Emergent BioSolutions(U.S.) Latest Developments
Table 66. GlaxoSmithKline(U.K.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 67. GlaxoSmithKline(U.K.) Inactivated Vaccine Product Offered
Table 68. GlaxoSmithKline(U.K.) Main Business
Table 69. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. GlaxoSmithKline(U.K.) Latest Developments
Table 71. Johnson & Johnson(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 72. Johnson & Johnson(U.S.) Inactivated Vaccine Product Offered
Table 73. Johnson & Johnson(U.S.) Main Business
Table 74. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Johnson & Johnson(U.S.) Latest Developments
Table 76. MedImmune(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 77. MedImmune(U.S.) Inactivated Vaccine Product Offered
Table 78. MedImmune(U.S.) Main Business
Table 79. MedImmune(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. MedImmune(U.S.) Latest Developments
Table 81. Merck & Co(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 82. Merck & Co(U.S.) Inactivated Vaccine Product Offered
Table 83. Merck & Co(U.S.) Main Business
Table 84. Merck & Co(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. Merck & Co(U.S.) Latest Developments
Table 86. Pfizer(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 87. Pfizer(U.S.) Inactivated Vaccine Product Offered
Table 88. Pfizer(U.S.) Main Business
Table 89. Pfizer(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Pfizer(U.S.) Latest Developments
Table 91. Sanofi Pasteur(France) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 92. Sanofi Pasteur(France) Inactivated Vaccine Product Offered
Table 93. Sanofi Pasteur(France) Main Business
Table 94. Sanofi Pasteur(France) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Sanofi Pasteur(France) Latest Developments
Table 96. Serum Institute of India Pvt(India) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 97. Serum Institute of India Pvt(India) Inactivated Vaccine Product Offered
Table 98. Serum Institute of India Pvt(India) Main Business
Table 99. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. Serum Institute of India Pvt(India) Latest Developments
.
Table 1. Inactivated Vaccine Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Children Inactivated Vaccine
Table 3. Major Players of Adult Inactivated Vaccine
Table 4. Inactivated Vaccine Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 7. Inactivated Vaccine Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 10. Global Inactivated Vaccine Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Inactivated Vaccine Revenue Market Share by Player (2019-2024)
Table 12. Inactivated Vaccine Key Players Head office and Products Offered
Table 13. Inactivated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Inactivated Vaccine Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Inactivated Vaccine Market Size Market Share by Regions (2019-2024)
Table 18. Global Inactivated Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Inactivated Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Inactivated Vaccine Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Inactivated Vaccine Market Size Market Share by Country (2019-2024)
Table 22. Americas Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 24. Americas Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 26. APAC Inactivated Vaccine Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Inactivated Vaccine Market Size Market Share by Region (2019-2024)
Table 28. APAC Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 30. APAC Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 32. Europe Inactivated Vaccine Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Inactivated Vaccine Market Size Market Share by Country (2019-2024)
Table 34. Europe Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 36. Europe Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Inactivated Vaccine Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Inactivated Vaccine Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Inactivated Vaccine Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Inactivated Vaccine Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Inactivated Vaccine
Table 45. Key Market Challenges & Risks of Inactivated Vaccine
Table 46. Key Industry Trends of Inactivated Vaccine
Table 47. Global Inactivated Vaccine Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Inactivated Vaccine Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Inactivated Vaccine Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Inactivated Vaccine Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Astellas Pharma(Japan) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 52. Astellas Pharma(Japan) Inactivated Vaccine Product Offered
Table 53. Astellas Pharma(Japan) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Astellas Pharma(Japan) Main Business
Table 55. Astellas Pharma(Japan) Latest Developments
Table 56. CSL Limited(Australia) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 57. CSL Limited(Australia) Inactivated Vaccine Product Offered
Table 58. CSL Limited(Australia) Main Business
Table 59. CSL Limited(Australia) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. CSL Limited(Australia) Latest Developments
Table 61. Emergent BioSolutions(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 62. Emergent BioSolutions(U.S.) Inactivated Vaccine Product Offered
Table 63. Emergent BioSolutions(U.S.) Main Business
Table 64. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Emergent BioSolutions(U.S.) Latest Developments
Table 66. GlaxoSmithKline(U.K.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 67. GlaxoSmithKline(U.K.) Inactivated Vaccine Product Offered
Table 68. GlaxoSmithKline(U.K.) Main Business
Table 69. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. GlaxoSmithKline(U.K.) Latest Developments
Table 71. Johnson & Johnson(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 72. Johnson & Johnson(U.S.) Inactivated Vaccine Product Offered
Table 73. Johnson & Johnson(U.S.) Main Business
Table 74. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Johnson & Johnson(U.S.) Latest Developments
Table 76. MedImmune(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 77. MedImmune(U.S.) Inactivated Vaccine Product Offered
Table 78. MedImmune(U.S.) Main Business
Table 79. MedImmune(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. MedImmune(U.S.) Latest Developments
Table 81. Merck & Co(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 82. Merck & Co(U.S.) Inactivated Vaccine Product Offered
Table 83. Merck & Co(U.S.) Main Business
Table 84. Merck & Co(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. Merck & Co(U.S.) Latest Developments
Table 86. Pfizer(U.S.) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 87. Pfizer(U.S.) Inactivated Vaccine Product Offered
Table 88. Pfizer(U.S.) Main Business
Table 89. Pfizer(U.S.) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Pfizer(U.S.) Latest Developments
Table 91. Sanofi Pasteur(France) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 92. Sanofi Pasteur(France) Inactivated Vaccine Product Offered
Table 93. Sanofi Pasteur(France) Main Business
Table 94. Sanofi Pasteur(France) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Sanofi Pasteur(France) Latest Developments
Table 96. Serum Institute of India Pvt(India) Details, Company Type, Inactivated Vaccine Area Served and Its Competitors
Table 97. Serum Institute of India Pvt(India) Inactivated Vaccine Product Offered
Table 98. Serum Institute of India Pvt(India) Main Business
Table 99. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. Serum Institute of India Pvt(India) Latest Developments
LIST OF FIGURES
.
Figure 1. Inactivated Vaccine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Inactivated Vaccine Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Inactivated Vaccine Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Inactivated Vaccine Sales Market Share by Country/Region (2023)
Figure 8. Inactivated Vaccine Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Inactivated Vaccine Market Size Market Share by Type in 2023
Figure 10. Inactivated Vaccine in Hospital
Figure 11. Global Inactivated Vaccine Market: Hospital (2019-2024) & ($ Millions)
Figure 12. Inactivated Vaccine in Medical Center
Figure 13. Global Inactivated Vaccine Market: Medical Center (2019-2024) & ($ Millions)
Figure 14. Global Inactivated Vaccine Market Size Market Share by Application in 2023
Figure 15. Global Inactivated Vaccine Revenue Market Share by Player in 2023
Figure 16. Global Inactivated Vaccine Market Size Market Share by Regions (2019-2024)
Figure 17. Americas Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 18. APAC Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 19. Europe Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 20. Middle East & Africa Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 21. Americas Inactivated Vaccine Value Market Share by Country in 2023
Figure 22. United States Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 23. Canada Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 24. Mexico Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 25. Brazil Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 26. APAC Inactivated Vaccine Market Size Market Share by Region in 2023
Figure 27. APAC Inactivated Vaccine Market Size Market Share by Type in 2023
Figure 28. APAC Inactivated Vaccine Market Size Market Share by Application in 2023
Figure 29. China Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 30. Japan Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 31. Korea Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 32. Southeast Asia Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 33. India Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 34. Australia Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 35. Europe Inactivated Vaccine Market Size Market Share by Country in 2023
Figure 36. Europe Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Figure 37. Europe Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Figure 38. Germany Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 39. France Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 40. UK Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 41. Italy Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 42. Russia Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 43. Middle East & Africa Inactivated Vaccine Market Size Market Share by Region (2019-2024)
Figure 44. Middle East & Africa Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Figure 45. Middle East & Africa Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Figure 46. Egypt Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 47. South Africa Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 48. Israel Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 49. Turkey Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 50. GCC Country Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 51. Americas Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 52. APAC Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 53. Europe Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 54. Middle East & Africa Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 55. United States Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 56. Canada Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 57. Mexico Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 58. Brazil Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 59. China Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 60. Japan Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 61. Korea Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 62. Southeast Asia Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 63. India Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 64. Australia Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 65. Germany Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 66. France Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 67. UK Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 68. Italy Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 69. Russia Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 70. Spain Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 71. Egypt Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 72. South Africa Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 73. Israel Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 74. Turkey Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 75. GCC Countries Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 76. Global Inactivated Vaccine Market Size Market Share Forecast by Type (2025-2030)
Figure 77. Global Inactivated Vaccine Market Size Market Share Forecast by Application (2025-2030)
.
Figure 1. Inactivated Vaccine Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Inactivated Vaccine Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Inactivated Vaccine Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Inactivated Vaccine Sales Market Share by Country/Region (2023)
Figure 8. Inactivated Vaccine Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Inactivated Vaccine Market Size Market Share by Type in 2023
Figure 10. Inactivated Vaccine in Hospital
Figure 11. Global Inactivated Vaccine Market: Hospital (2019-2024) & ($ Millions)
Figure 12. Inactivated Vaccine in Medical Center
Figure 13. Global Inactivated Vaccine Market: Medical Center (2019-2024) & ($ Millions)
Figure 14. Global Inactivated Vaccine Market Size Market Share by Application in 2023
Figure 15. Global Inactivated Vaccine Revenue Market Share by Player in 2023
Figure 16. Global Inactivated Vaccine Market Size Market Share by Regions (2019-2024)
Figure 17. Americas Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 18. APAC Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 19. Europe Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 20. Middle East & Africa Inactivated Vaccine Market Size 2019-2024 ($ Millions)
Figure 21. Americas Inactivated Vaccine Value Market Share by Country in 2023
Figure 22. United States Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 23. Canada Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 24. Mexico Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 25. Brazil Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 26. APAC Inactivated Vaccine Market Size Market Share by Region in 2023
Figure 27. APAC Inactivated Vaccine Market Size Market Share by Type in 2023
Figure 28. APAC Inactivated Vaccine Market Size Market Share by Application in 2023
Figure 29. China Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 30. Japan Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 31. Korea Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 32. Southeast Asia Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 33. India Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 34. Australia Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 35. Europe Inactivated Vaccine Market Size Market Share by Country in 2023
Figure 36. Europe Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Figure 37. Europe Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Figure 38. Germany Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 39. France Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 40. UK Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 41. Italy Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 42. Russia Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 43. Middle East & Africa Inactivated Vaccine Market Size Market Share by Region (2019-2024)
Figure 44. Middle East & Africa Inactivated Vaccine Market Size Market Share by Type (2019-2024)
Figure 45. Middle East & Africa Inactivated Vaccine Market Size Market Share by Application (2019-2024)
Figure 46. Egypt Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 47. South Africa Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 48. Israel Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 49. Turkey Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 50. GCC Country Inactivated Vaccine Market Size Growth 2019-2024 ($ Millions)
Figure 51. Americas Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 52. APAC Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 53. Europe Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 54. Middle East & Africa Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 55. United States Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 56. Canada Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 57. Mexico Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 58. Brazil Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 59. China Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 60. Japan Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 61. Korea Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 62. Southeast Asia Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 63. India Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 64. Australia Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 65. Germany Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 66. France Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 67. UK Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 68. Italy Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 69. Russia Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 70. Spain Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 71. Egypt Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 72. South Africa Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 73. Israel Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 74. Turkey Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 75. GCC Countries Inactivated Vaccine Market Size 2025-2030 ($ Millions)
Figure 76. Global Inactivated Vaccine Market Size Market Share Forecast by Type (2025-2030)
Figure 77. Global Inactivated Vaccine Market Size Market Share Forecast by Application (2025-2030)
More Publications
Global Tissue Testing Market Growth 2024-2030
US$ 3,660.00
September 2024
114 pages
Global Hormone Refractory Prostate Cancer (HRPCA) Market Growth (Status and Outlook) 2023-2029
US$ 3,660.00
February 2023
64 pages
Global Genome Editing and Genome Engineering Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
December 2024
111 pages
Global Medical Second Opinion Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
January 2025
131 pages
Global Chemical Medication in COVID-19 Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
December 2024
126 pages
